Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic

Hoth Therapeutics, a biopharmaceutical company focused on patient care, has recently received protocol approval for its cancer therapeutic, HT-001. This exciting development was announced on July 19, 2023. &nbsp The FDA-approved trial now has two sites approved for conducting the study, and additional sites are currently in the approval process. This means that recruitment of patients can now be..

  • format_list_bulleted BS
  • · 2023. 7. 19.
  • textsms

Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site

Hoth Therapeutics has received approval from the University of Texas MD Anderson Cancer Center Institutional Review Board (IRB) to proceed with its First-in-Human Phase 2a clinical trial of HT-001. This milestone marks multiple sites hosting the trial, as Washington University of St Louis previously approved it as well. The randomized, placebo-controlled, parallel Phase 2a dose-ranging study aim..

  • format_list_bulleted BS
  • · 2023. 6. 15.
  • textsms